非ホジキンリンパ腫の世界市場-2023年～2030年

市場概要

世界の非ホジキンリンパ腫市場は、2022年に73億米ドルに達し、2030年には135億米ドルに達し、有利な成長が予測されています。世界の非ホジキンリンパ腫市場は、予測期間中（2023～2030年）に8.2％のCAGRを示すと予測されます。

非ホジキンリンパ腫市場では、標的療法の開拓と商業化が注目されています。非ホジキンリンパ腫ではバイオマーカーの同定と利用が牽引役となっており、一方、治療の有効性と価値を評価する上で実臨床でのエビデンスの構築がますます重要になっています。これらの動向は、個別化されたアプローチ、転帰の改善、治療のペイシェントジャーニーを通じた患者体験の向上に焦点を当て、NHL治療の進化する状況を形成しています。

さらに、非ホジキンリンパ腫市場は、革新的な治療アプローチの開拓、非ホジキンリンパ腫の生物学を理解するための広範な研究開発努力、医療サービスへのアクセスを強化し、有利な償還制度を提供することを目的とした政府の支援政策によって牽引されています。

市場力学

FDA認可の増加が世界の非ホジキンリンパ腫市場を牽引する見込み

ロシュ・グループ傘下のジェネンテックは2022年7月5日、米国食品医薬品局（FDA）がモスネツズマブの生物製剤承認申請（BLA）を受理し、優先審査権を付与したと発表しました。このファースト・イン・クラスのCD20xCD3 T細胞結合二重特異性抗体は、少なくとも2回の全身療法を受けた再発または難治性の濾胞性リンパ腫（FL）の治療薬として評価されています。

濾胞性リンパ腫は非ホジキンリンパ腫（NHL）の中で最も一般的な低悪性度型で、初回治療後の増殖が遅く、再発が多いという特徴があります。FDAは2022年12月29日までに、新規がん免疫療法であるモスネツズマブの承認を決定する予定です。

同様に、2022年12月22日、ギリアド社傘下のカイトファーマ社と第一三共株式会社は共同で、日本におけるモスネツズマブ（一般名）の承認取得を発表した、は、キメラ抗原受容体（CAR）T細胞療法であるイエスカルタ（一般名：axicabtagene ciloleucel）を、再発・難治性の大細胞型B細胞リンパ腫（びまん性大細胞型B細胞リンパ腫、原発性縦隔大細胞型B細胞リンパ腫、形質転換濾胞性リンパ腫、高悪性度B細胞リンパ腫）の初回治療薬として厚生労働省に承認されたと発表しました。

イエスカルタは、CD19抗原を標的とするCAR T細胞の輸注を受けたことのない患者にのみ使用されるべきです。したがって、FDA承認の増加は世界の非ホジキンリンパ腫市場を牽引すると予想されます。

非ホジキンリンパ腫の治療と早期病勢進行リスクの予測に関する調査の進展が世界の非ホジキンリンパ腫市場を牽引すると期待される

2023年1月25日に発表された米国臨床腫瘍学会（ASCO）の記事によると、ルイジアナ州ニューオーリンズで12月10日から13日まで開催された2022年米国血液学会（ASH）年次総会・博覧会では、非ホジキンリンパ腫の分野で重要な研究成果が発表されました。

さらに、リンパ腫患者の早期病勢進行の予測に焦点を当てた2つの研究が行われました。最初の研究はFLIPI24モデルを導入したもので、年齢、ヘモグロビン値、白血球数、乳酸脱水素酵素値、β2ミクログロブリン値などの因子を利用して、早期病勢進行リスクのある濾胞性リンパ腫患者を同定しました。

2番目の研究では、ゲノムベースのモデルであるCCP-32予測因子を利用して、早期病勢進行のリスクがあるびまん性大細胞型B細胞リンパ腫患者を同定しました。ASH年次総会で発表されたこれらの調査結果は、非ホジキンリンパ腫の新たな治療アプローチや、早期病勢進行リスクのある患者の同定に役立つ予測モデルに関する貴重な知見を提供するものです。このように、上記の要因により、予測期間中、市場は拡大すると予想されます。

非ホジキンリンパ腫における薬剤耐性という重大な課題が世界の非ホジキンリンパ腫市場を阻害する見込み

非ホジキンリンパ腫（NHL）における薬剤耐性は、がん細胞が適応して特定の治療法の効果に耐性を持つようになることで発生します。この耐性は、遺伝子変異、薬物標的の変化、代替シグナル伝達経路の活性化、DNA修復機構の強化など、様々なメカニズムから生じる可能性があります。薬剤耐性は治療失敗、病勢進行、患者の治療選択肢の制限につながるため、非ホジキンリンパ腫の管理において重要な課題となります。

非ホジキンリンパ腫における薬剤耐性の一例は、化学療法を受けている患者に認められ、具体的にはアントラサイクリン系薬剤と呼ばれる種類の薬剤です。アントラサイクリン系薬剤は、びまん性大細胞型B細胞リンパ腫（DLBCL）を含む非ホジキンリンパ腫の治療に一般的に使用されています。しかし、一部のDLBCL患者はアントラサイクリン系薬剤に対する耐性を獲得する可能性があり、治療失敗や予後不良につながります。

COVID-19の影響分析

COVID-19の大流行は非ホジキンリンパ腫（NHL）市場に大きな影響を与えました。パンデミックの最盛期には、多くのヘルスケアシステムが圧倒され、緊急性のない医療処置やスクリーニングは延期または中止されました。このため、非ホジキンリンパ腫の診断や患者の治療開始が遅れました。その結果、一部の非ホジキンリンパ腫は診断が遅れ、治療成績に影響を及ぼす可能性があります。

臨床試験は、新しい治療法を開発し、非ホジキンリンパ腫の予後を改善するために不可欠です。しかし、パンデミックにより臨床試験の実施は中断され、多くの施設が一時的に登録を中止したり、患者の安全を優先するためにプロトコールを変更したりしました。このため、臨床試験の完了が遅れ、新しい治療法の利用が遅れています。

さらに、研究開発の焦点はパンデミック中にシフトし、COVID-19に対するワクチンや治療法の開発に重点が置かれました。このような資源と関心の転用は、一時的に非ホジキンリンパ腫関連の研究開発活動の進展に影響を与えた可能性があります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、ヘルスケアや非ホジキンリンパ腫（NHL）などの疾患の管理を含め、両国の生活の様々な側面に重大な影響を及ぼしています。紛争は、影響を受けた地域のヘルスケアインフラの破壊と崩壊につながっています。病院や診療所を含む医療施設が被害を受けたり、アクセスできなくなったりしたため、非ホジキンリンパ腫患者が適切な診断、治療、経過観察を受けることが困難になっています。

紛争の結果、診断機器、薬剤、専門的なヘルスケア専門家を含む医療資源の利用が制限されました。この乏しさは、診断の遅れ、不十分な治療選択肢、NHL患者にとって最適でない疾病管理につながる可能性があります。

紛争は人口の移動をもたらし、人々は家を離れ、安全な地域に避難することを余儀なくされています。この移住は、患者が通常の医療提供者や治療施設にアクセスすることを困難にし、NHL治療の中断につながる可能性があるため、患者のケアの継続性を乱す可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 非ホジキンリンパ腫に対する薬事承認の増加
    • 非ホジキンリンパ腫治療薬の臨床試験の増加
  • 抑制要因
    • 非ホジキンリンパ腫治療のための特異的標的治療薬の欠如
  • 機会
    • 非ホジキンリンパ腫治療強化のための併用療法の探求
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 疾患タイプ別

• B細胞リンパ腫
• T細胞リンパ腫

第9章 薬剤クラス別

• モノクローナル抗体
• 抗体-薬物複合体
• BTK/BCL-2キナーゼ阻害薬
• PI3キナーゼ阻害薬
• プロテアーゼ阻害剤
• PD1阻害剤
• 免疫調節薬
• 化学療法剤
• CAR T細胞療法

第10章 投与経路別

• 経口
• 非経口
• その他

第11章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• AbbVie, Inc.（Pharmacyclics LLC）
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company（Celgene Corp.）
• Gilead Sciences, Inc.（Kite Pharma）
• Johnson & Johnson（Janssen Biotech, Inc.）
• Merck & Co., Inc.
• Novartis AG
• Roche Holding AG（F. Hoffmann-La Roche AG）
• Seagen, Inc.（Seattle Genetics, Inc.）
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.

第15章 付録

Market Overview

The Global Non-Hodgkin Lymphoma Market reached US$ 7.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 13.5 billion by 2030. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

The NHL market has witnessed a notable emphasis on the development and commercialization of targeted therapies. Biomarker identification and utilization have gained traction in NHL while generating real-world evidence has become increasingly important in assessing treatment effectiveness and value. These trends collectively shape the evolving landscape of NHL treatment, with a focus on personalized approaches, improved outcomes, and enhancing the patient experience throughout their treatment journey.

Furthermore, the NHL market is driven by the development of innovative treatment approaches, extensive research and development efforts to understand NHL biology, and supportive government policies that aim to enhance access to healthcare services and provide favorable reimbursement systems.

Market Dynamics

The Increasing FDA Approvals are Expected to Drive Global Non-Hodgkin Lymphoma Market

Genentech, a member of the Roche Group, announced on July 5, 2022, that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) and granted Priority Review for mosunetuzumab. This potential first-in-class CD20xCD3 T-cell engaging bispecific antibody is being evaluated for the treatment of adults with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior systemic therapies.

FL is the most common indolent form of non-Hodgkin's lymphoma (NHL), characterized by slow growth and frequent recurrence after initial treatment. The FDA is expected to decide on the approval of mosunetuzumab, a novel cancer immunotherapy, by December 29, 2022.

Similarly, on December 22, 2022, Kite Pharma, Inc., a Gilead Company and Daiichi Sankyo Co., Ltd, jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Yescarta should be used only in patients who have not received a prior transfusion of CAR T-cells targeted at the CD19 antigen. Therefore, the increasing FDA approvals are expected to drive the global non-Hodgkin lymphoma market.

Advancing Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of Early Disease Progression is Expected to Drive Global Non-Hodgkin Lymphoma Market

According to the American Society of Clinical Oncology (ASCO) Article, published on January 25, 2023, during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, which took place from December 10 to 13 in New Orleans, Louisiana, significant research findings in the field of non-Hodgkin lymphoma were presented.

Additionally, two studies focused on predicting early disease progression in lymphoma patients. The first study introduced the FLIPI24 model, which utilized factors such as age, hemoglobin levels, white blood cell count, lactate dehydrogenase levels, and beta-2-microglobulin levels to identify follicular lymphoma patients at risk for early disease progression.

The second study utilized the CCP-32 predictor, a genomic-based model, to identify diffuse large B-cell lymphoma patients who may be at risk for early disease progression. These research findings presented at the ASH Annual Meeting provide valuable insights into new treatment approaches for non-Hodgkin lymphoma and predictive models that aid in identifying patients at risk for early disease progression. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Significant Challenges Possessed with Drug Resistance in NHL Expected to Hamper Global Non-Hodgkin Lymphoma Market

Drug resistance in Non-Hodgkin Lymphoma (NHL) occurs when the cancer cells adapt and become resistant to the effects of a particular treatment. This resistance can result from various mechanisms, including genetic mutations, alterations in drug targets, activation of alternative signaling pathways, or enhanced DNA repair mechanisms. Drug resistance poses a significant challenge in managing NHL, as it can lead to treatment failure, disease progression, and limited treatment options for patients.

An example of drug resistance in NHL is observed in patients receiving chemotherapy, specifically, the class of drugs called anthracyclines. Anthracyclines are commonly used in the treatment of NHL, including Diffuse Large B-cell Lymphoma (DLBCL). However, some DLBCL patients may develop resistance to anthracyclines, leading to treatment failure and a poorer prognosis.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Non-Hodgkin Lymphoma (NHL) market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of NHL and initiation of treatment for patients. As a result, some NHL cases have been diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in NHL. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of NHL-related research and development activities.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of diseases such as non-Hodgkin lymphoma (NHL). The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, were damaged or inaccessible, making it challenging for patients with NHL to receive proper diagnosis, treatment, and follow-up care.

The conflict resulted in limited availability of medical resources, including diagnostic equipment, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for NHL patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their NHL treatment.

Segment Analysis

The global non-Hodgkin lymphoma market is segmented based on disease type, drug class, route of administration, distribution channel, and region.

CAR T-Cell Therapy from the Drug Class Segment Accounts for 20.5% of the Market Share Owing to the Rapidly Evolving Treatment Approach, and Increasing Clinical Trials

CAR T-cell therapy has emerged as a highly promising and rapidly evolving treatment approach for certain types of Non-Hodgkin Lymphoma (NHL). CAR T-cell therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that specifically target cancer cells. These engineered T cells are then infused back into the patient, where they recognize and destroy cancer cells.

CAR T-cell therapy has shown remarkable efficacy in the treatment of B-cell malignancies, including certain subtypes of NHL, such as Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). For example, the CAR T-cell therapy products axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have been approved by regulatory authorities for the treatment of relapsed or refractory DLBCL and FL.

The adoption of CAR T-cell therapy has rapidly increased due to its impressive clinical outcomes, including high response rates and durable remissions in patients who have failed other treatments. However, it is important to note that CAR T-cell therapy is currently approved for specific indications and is not suitable for all NHL patients. It is primarily used in cases where other treatment options have been exhausted or have failed.

Furthermore, in 2022, an interventional trial with the identifier ML43165 was conducted by Lazaros Lekakis. The trial is a single-arm Phase 2 study that aims to evaluate the efficacy of an FDA-approved anti-CD19 CAR-T therapy followed by consolidation treatment with mosunetuzumab and polatuzumab in patients with refractory or relapsed aggressive Non-Hodgkin Lymphoma (NHL). The estimated completion date for this study is December 2027. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.9% of the Market Share Owing to the Rising incidences of NHL and Several Therapy Approvals

The increasing incidences of NHL, several therapy approvals, the growing awareness of the disease, and increasing clinical trials are expected to drive the North American region over the forecast period.

For instance, on April 19, 2023, the U.S. Food and Drug Administration (FDA) announced it has approved elotuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater.

Similarly, on April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma.

Competitive Landscape

The major global players in the market include: AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others.

Why Purchase the Report?

• To visualize the global non-Hodgkin lymphoma market segmentation based on the disease type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of non-Hodgkin lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global non-Hodgkin lymphoma market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Growing Regulatory Approvals for Non-Hodgkin Lymphoma
    • 4.1.1.2. The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma
  • 4.1.3. Opportunity
    • 4.1.3.1. Exploring Combination Therapies for Enhanced Non-Hodgkin Lymphoma Treatment
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Disease Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 8.1.2. Market Attractiveness Index, By Disease Type
• 8.2. B-cell Lymphomas*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. T-cell Lymphoma

9. By Drug Class

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.1.2. Market Attractiveness Index, By Drug Class
• 9.2. Monoclonal Antibodies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Antibody-Drug Conjugates
• 9.4. BTK/BCL-2 Kinase Inhibitors
• 9.5. PI3 Kinase Inhibitors
• 9.6. Protease Inhibitors
• 9.7. PD1 Inhibitors
• 9.8. Immunomodulatory Drugs
• 9.9. Chemotherapy Agents
• 9.10. CAR T-Cell Therapy

10. By Route of Administration

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.1.2. Market Attractiveness Index, By Route of Administration
• 10.2. Oral*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Parenteral
• 10.4. Others

11. By Distribution Channel

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
• 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. The U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. The U.K.
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.4.7.1. Brazil
    • 12.4.7.2. Argentina
    • 12.4.7.3. Rest of South America
• 12.5. Asia Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.5.7.1. China
    • 12.5.7.2. India
    • 12.5.7.3. Japan
    • 12.5.7.4. Australia
    • 12.5.7.5. Rest of Asia Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. AbbVie, Inc. (Pharmacyclics LLC) *
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. AstraZeneca plc
• 14.3. Bayer AG
• 14.4. Bristol-Myers Squibb Company (Celgene Corp.)
• 14.5. Gilead Sciences, Inc. (Kite Pharma)
• 14.6. Johnson & Johnson (Janssen Biotech, Inc.)
• 14.7. Merck & Co., Inc.
• 14.8. Novartis AG
• 14.9. Roche Holding AG (F. Hoffmann-La Roche AG)
• 14.10. Seagen, Inc. (Seattle Genetics, Inc.)
• 14.11. Takeda Pharmaceutical Co., Ltd.
• 14.12. Teva Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us